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Abstract
Background:  Nephron-sparing  surgery  is  currently  the  treatment  of  choice  for  surgical  removal
of solid  renal  tumours  smaller  than  7  cm,  in  the  case  of  a  solitary  kidney,  bilateral  renal  tumours
or the  presence  of  chronic  renal  failure.
Material  and  methods: An  observational,  descriptive,  retrospective  and  cross-sectional  study
was conducted.  The  variables  evaluated  were:  age  at  diagnosis,  gender,  intraoperative  blood
loss, operative  time,  preoperative  tumour  size,  hospital  stay,  pathology  report,  pTNM  classiﬁ-
cation, Fuhrman  nuclear  grade,  pre-  and  post-operative  creatinine,  monitoring  for  cancer.  All
were analysed  using  SPSS  v  22.
Results:  The  study  included  28  patients,  14  male  and  14  women,  with  a  mean  age  52.3  years.
The approach  was  lumbotomy  in  all  patients.  The  mean  hospital  stay  was  4.1  days.  Mean
perioperative  bleeding  loss  was  380.3  ml.  The  mean  preoperative  creatinine  was  0.96  mg/dl,
with a  post-operative  mean  of  1.12  mg/dl.  Histopathology  reported,  23  clear  cell  tumours,  2
angiomyolipomas,  2  oncocytomas,  and  1  haemorrhagic  cyst.  Tumour  staging  was  performed  on
14 patients,  with  13  patients  T1bN0M0,  and  1  patient  T2aN0M0.  In  clear  cell  tumours,  Fuhrman
nuclear grade  2  was  present  in  16  patients  and  7  patients  were  Fuhrman  grade  3.
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Conclusion:  Nephron  sparing  surgery  is  the  choice  procedure  of  choice  in  patients  with  small
renal tumours,  with  good  functional  results  without  signiﬁcant  alteration  in  renal  function.
Outcome  is  optimal,  with  a  low  incidence  of  complications.
© 2015  Academia  Mexicana  de  Cirugía  A.C.  Published  by  Masson  Doyma  México  S.A.  This
is an  open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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Experiencia  en  cirugía  preservadora  de  nefronas  en  pacientes  con  tumores  renales
pequen˜os
Resumen
Antecedentes:  La  nefrectomía  radical  es  considerada  el  estándar  de  oro  para  el  tratamiento  de
tumores renales.  Sin  embargo,  la  cirugía  preservadora  de  nefronas  es  una  opción  quirúrgica  en
pacientes con  tumores  renales  menores  de  7  cm,  con  rin˜ón  único,  tumores  renales  bilaterales
o con  insuﬁciencia  renal  crónica.
Objetivo:  Describimos  la  experiencia  en  cirugía  preservadora  de  nefronas  en  pacientes  con
tumores  renales  pequen˜os  (<7  cm).
Material  y  métodos:  Estudio  observacional,  descriptivo,  retrolectivo  y  transversal.  Varia-
bles estudiadas:  edad  al  diagnóstico,  género,  sangrado  transoperatorio,  tiempo  quirúrgico,
taman˜o tumoral  prequirúrgico,  estancia  intrahospitalaria,  resultado  histopatológico,  clasiﬁ-
cación pTNM,  grado  nuclear  de  Furhman,  creatinina  antes  y  después  de  la  cirugía,  seguimiento
oncológico.  Análisis  estadístico  con  programa  SPSS  v22.
Resultados:  Se  incluyeron  28  pacientes,  14  hombres  y  14  mujeres.  Edad  promedio  52.3  an˜os,
el abordaje  fue  lumbotomía  en  todos  los  pacientes.  Promedio  de  4.1  días  de  estancia  intra-
hospitalaria.  Promedio  de  sangrado  transoperatorio  de  380.3  ml.  La  creatinina  en  promedio:
antes de  cirugía  0.96  mg/dl,  y  después  de  1.12  mg/dl.  Resultado  de  histopatología:  23  tumores
de células  claras,  2  angiomiolipomas,  2  oncocitomas  y  1  quiste  hemorrágico.  14  pacientes  se
presentaron  en  etapa  T1aN0M0,  13  pacientes  T1bN0M0,  1  paciente  T2aN0M0.
En los  tumores  de  células  claras,  el  grado  nuclear  Furhman  2  se  presentó  en  16  pacientes  y
Furhman 3  en  7.
Conclusión:  La  cirugía  preservadora  de  nefronas  es  el  procedimiento  de  elección  en  pacientes
con tumores  renales  pequen˜os,  por  buenos  resultados  funcionales  (sin  alteración  signiﬁcativa  en
la función  renal),  con  adecuado  control  oncológico,  con  mínima  incidencia  de  complicaciones.
© 2015  Academia  Mexicana  de  Cirugía  A.C.  Publicado  por  Masson  Doyma  México  S.A.  Este
es un  artículo  Open  Access  bajo  la  licencia  CC  BY-NC-ND  (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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idney  tumours  represent  approximately  2--3%  of  all  solid
eoplasias.  Each  year  8.9  new  cases  every  100,000  are  diag-
osed  and  over  11,000  deaths  are  reported.  Its  incidence  has
ncreased  from  2  to  4%  due  to  the  use  of  imaging  techniques.
t  is  more  common  in  men  by  a  3:2  ratio;  the  mean  age  at
he  time  of  diagnosis  is  65  years.1
As  for  renal  cell  carcinomas,  it  is  believed  that  they
ainly  arise  from  proximal  tubule  cells,  and  this  is  prob-
bly  correct  for  clear  cell  and  variants  of  papillary  ones.
owever,  other  histological  subtypes  of  renal  cell  carcino-
as,  such  as  chromophobe  and  collecting  duct  ones,  derive
rom  more  distal  components  of  the  nephron.2
Tobacco  consumption  is  the  most  accepted  risk  factor  for
enal  cell  carcinoma,  and  causes  between  20  and  30%  kidney
arcinoma  cases  in  men  and  10--20%  in  women;  regardless
f  the  type  of  exposure,  it  has  been  shown  that  the  risk
ncreases  with  the  accumulated  dose  and  the  relative  risk  is
a
d
s
mirectly  linked  to  the  length  of  time  the  patient  has  had  this
abit.  Other  risk  factors  in  order  of  importance  are:  obesity,
igh  blood  pressure,  and  in  a  lower  proportion,  it  is  associ-
ted  with  urban  and  industrial  settings  and  with  exposure
o  industrial  solvents  (trichloroethylene),  as  well  as  with
roducts  from  the  footwear  and  fur  industries,  asbestos,
admium,  petroleum  and  gasoline.  A  family  history  of  renal
arcinoma  is  a  non-modiﬁable  risk  factor  (2--5%),2 mainly  for
ultifocal  or  bilateral  cases.
The  probability  of  having  mutations  in  geneVHL  for
poradic  tumours  is  69%,  and  in  another  20%  there  is  hyper-
ethylation  of  this  gene.  Von  Hippel--Lindau  syndrome  is
ssociated  with  a  50%  incidence  of  renal  cell  carcinoma,  and
lso  to  multiple  and  bilateral  tumours  by  80%.3
More  than  30%  of  the  kidney  tumours  are  asymptomatic
nd  are  diagnosed  during  the  end  stage;  in  50%  of  the  cases
iagnosis  is  incidental  when  performing  abdominal  imaging
tudies  for  another  disease.  In  asymptomatic  patients,  the
anifestations  are  variable  and  can  be  unspeciﬁc.  It  should
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DExperience  in  nephron-sparing  surgery  in  patients  with  smal
be  suspected  in  the  presence  of  an  abdominal  tumour,  a  cer-
vical  adenopathy,  a  varicocele  that  does  not  decrease  in  size
with  conventional  manoeuvres,  bilateral  oedema  in  lower
limbs  (sign  of  venous  involvement).  In  cases  with  metastatic
involvement  there  can  be  bone  pain  or  persistent  cough.
30%  of  the  patients  with  symptomatic  kidney  cancer  have
paraneoplastic  syndromes  characterised  by  hypercalcaemia,
high  blood  pressure,  polycythaemia  and  Stauffer  syndrome.
In  the  majority  of  cases,  the  diagnosis  is  established
based  on  the  results  of  a  contrast  CT  scan.  This  is  the
standard  method,  since  the  unique  strengthening  of  the
tumour  is  seen  because  of  the  contrast  material.  The
strengthening  of  renal  masses  is  determined  by  comparing
the  values  of  the  Hounsﬁeld  units  obtained  before  and  after
administration  of  the  contrast  material.  A  magnetic  reso-
nance  can  provide  additional  data  if  the  CT  scan  results  are
unspeciﬁc.4
To  establish  a  diagnosis  and  be  able  to  administer  ade-
quate  treatment,  it  is  essential  to  perform  a  ﬁne-needle
aspiration  biopsy,  which  has  80--95%  accuracy.  Its  most
important  indication  is  the  differentiation  between  renal
carcinoma  and  metastatic  disease  or  renal  lymphoma.4
Fuhrman  grade  (Table  1)  is  one  of  the  most  important
prognosis  variables  in  all  kidney  cancer  stages;  it  is  a  survival
predictor  that  is  independent  from  the  pathological  stage,
which  is  only  applied  for  the  histological  clear  cell  subtype.
The  most  common  Fuhrman’s  nuclear  grades  are  2  and  3.
Grade  4  is  present  in  10%  and  grade  1  in  less  than  10%.5
A  better  understanding  of  the  biology  of  the  tumour,
its  staging  patterns  and  the  presentation  pattern  in
patients  with  renal  cell  carcinoma  allows  a  reﬁned  surgical
approach,  which  restricts  the  long-term  morbidity  poten-
tial  by  maximising  the  preservation  of  the  functional  renal
parenchyma.6
Nephron-sparing  surgery  has  become  an  effective  and
safe  alternative  to  radical  nephrectomy  and  can  be  applied
to  candidate  situations,  such  as  renal  disorders  associated
with  genetic  diseases,  monorenal  patients  or  patients  with
contralateral  kidney  disease.
Acceptable  indications  for  nephron-sparing  surgery  can
be  divided  into  three  categories,  which  include  absolute,
relative  and  elective  indications.  Absolutes:  this  must  be
taken  into  consideration  in  all  patients  with  localised  malig-
nant  tumours  which,  if  not  performed,  would  make  the
patient  anephric,  with  subsequent  and  immediate  need
for  renal  replacement  therapy.  Relatives:  contralateral  kid-
ney  affected  by  a  condition  that  can  lower  its  function  in
the  future  (risk  of  developing  contralateral  kidney  tumour,
multiple  tumours  with  bilateral  affection).  These  relative
indications  for  sparing  surgery  extend  to  patients  with  renal
d
s
M
t
Table  1  Classiﬁcation  of  Fuhrman’s  nuclear  grades.
Grade  Nucleus  size
(mm)
Nucleus  borders  (mm)  Nuc
1  10  Uniform  Abs
2 15  Irregular  Sm
3 20  Irregular  Pro
4 >20  Multilobular  Proal  tumours  299
ithiasis  disease,  chronic  pyelonephritis,  urethral  reﬂux,
enal  artery  stenosis,  high  blood  pressure,  diabetes  melli-
us  and  other  causes  of  glomerulopathy  or  nephrosclerosis.
lectives:  localised  unilateral  kidney  tumours  with  healthy
ontralateral  kidney.7
Nephron-sparing  surgery  has  proven  to  be  very  effective
or  the  treatment  of  small  kidney  tumours,  since  it  decreases
he  risk  of  chronic  renal  disease  in  patients  who  have  addi-
ional  associated  risk  factors.  The  subsequent  oncological
heck-up  shows  the  same  results  as  radical  nephrectomy,
or  which  complication  rates  are  higher  and  there  is  a  risk
f  renal  failure.  By  having  this  alternative  for  this  group
f  patients,  therapeutic  indication  is  reinforced  with  lower
isks  and  more  beneﬁts  in  the  renal  residual  preservation
f  the  affected  kidney,  with  long-term  improvement  of  the
rognosis.8
aterial and methods
bservational,  descriptive,  retrospective  and  cross-
ectional  study  for  the  period  between  January  1,  2010
nd  January  1,  2014.  The  experience  with  nephron-sparing
urgery  in  patients  with  small  kidney  tumours  (<7  cm)  at
he  Unidad  Médica  de  Alta  Especialidad,  Puebla,  from
he  Instituto  Mexicano  del  Seguro  Social  (IMSS).  Patients
rom  the  Urology  service  with  kidney  tumour  diagnosis
7  cm  and  who  underwent  nephron-sparing  surgery,  with
ull  clinical  records  and  full  variables  to  be  analysed  were
ncluded.
The  data  extracted  for  every  patient  were:  gender,  age,
ymptomatology,  comorbidities,  surgical  time,  extension
tudies,  intraoperative  bleeding,  histopathological  report,
uhrman’s  nuclear  grade,  tumour  size  and  pre-  and  postop-
rative  creatinine.
In the  statistical  analysis  a  descriptive  statistic  was  used:
verages,  standard  deviation  and  proportions.  The  results
rom  the  research  were  analysed  using  the  SPSS  v22.  pro-
ram.
Patients  who  underwent  other  types  of  surgery  for  kid-
ey  tumours  <7  cm  or  with  incomplete  clinical  records  were
xcluded.
esults
uring  the  period  of  study,  a  total  of  28  patients  with  a
iagnosis  of  kidney  tumour  <7  cm,  who  underwent  nephron-
paring  surgery  at  the  National  Centro  General  de  Salud
anuel  Ávila  Camacho  of  IMSS  in  Puebla  and  who  fulﬁlled
he  inclusion  criteria  were  included:  50%  were  males  (14)
leus  Disease-free  survival
after  ﬁve  years  (%)
ent  89
all  65
minent  46
minent,  chromatin  corpuscles  <46
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Table  2  Statistical  analysis:  age,  size  of  tumour,  intraoperative  bleeding,  operating  room  time.
Mean  Standard  deviation  Minimum  Maximum
Age  (years)  52.3  14.865  19  77
Tumour size  (cm)  4.4  0.8571  3  7
Intraoperative  bleeding  (ml)  380.3  112.5  200  650
Operating room  time  (h)  2.34  0.42  2  3
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(4%)  (Fig.  3).  In  patients  with  cell  tumours,  Fuhrman’s
nuclear  grade  2  was  most  common  for  16  patients  (70%)
and  seven  patients  were  Fuhrman’s  nuclear  grade  3  (30%)
(Fig.  4).
4%
82%
7%
7%
Clear cell Angiomyolipomas
Oncocytomas Haemorrhagic cyst
Histopathology results for
kidney tumoursigure  1  Preoperative  creatinine  levels  with  an  average  of  0
he average  postoperative  creatinine  level  was  of  1.12  mg/dl,  
nd  50%  were  females  (14).  The  average  age  was  52.3  years,
tandard  deviation  was  14.8,  and  the  range  19--77  years,
ith  a  maximum  follow-up  of  three  years  (Table  2).
Regarding  symptoms,  four  patients  had  macroscopic
aematuria,  14  pain  and  ten  patients  were  asymptomatic.
en  patients  had  a  history  of  tobacco  use.  There  was  one
onorenal  patient  due  to  left  renal  exclusion  caused  by
enal  lithiasis.  Comorbidities  were  high  blood  pressure  in  ten
atients  (36%),  diabetes  mellitus  in  six  (21%)  and  obesity  in
ight  patients  (29%).
The  average  operating  theatre  time  was  2.3  h  with  a
tandard  deviation  of  0.42  and  a  range  between  2  and  3  h.
he  average  tumour  size  was  of  4.4  cm,  with  a  standard  devi-
tion  of  0.85  and  a  range  between  3  and  7  cm;  5  cm  tumours
ere  more  common  in  nine  patients  (Table  2).
Extension  studies  were  negative  in  all  patients.  Surgical
pproach  in  100%  of  the  patients  was  by  lumbotomy.  The
ean  hospital  stay  was  4.1  days  with  a  minimum  of  three
nd  a  maximum  of  six  days.  Average  intraoperative  bleeding
as  380.3  ml,  with  a  standard  deviation  of  112.5  and  a  range
etween  200  and  650  ml  (Table  2).
Creatinine  levels  were  measured  before  surgery  with  an
verage  of  0.96  mg/dl:  a  minimum  of  0.5  mg/dl  and  a max-
mum  of  1.6  mg/dl.  Creatinine  levels  were  measured  after
urgery,  obtaining  an  average  of  1.12  mg/dl,  a  minimum  of
.7  mg/dl  and  a  maximum  of  1.6  mg/dl  (Fig.  1).
Histopathological  results:  82%  were  clear  cell  tumours
23),  7%  angiomyolipomas  (2),  7%  oncocytomas  (2)  and  4%
aemorrhagic  cysts  (1).  None  of  the  patients  had  positive
urgical  borders  (Fig.  2).
TNM  classiﬁcation  found  14  T1a  N0  M0  patients  (50%),
3  T1b  N0  M0  patients  (46%),  one  T2a  N0  M0  patient
F
c
rg/dl:  a  minimum  of  0.5  mg/dl  and  a  maximum  of  1.6  mg/dl.
a  minimum  of  0.7  mg/dl  and  a  maximum  of  1.6  mg/dl.igure  2  Reported  histological  percentages:  82%  were  clear
ell, 7%  angiomyolipomas,  7%  oncocytomas  and  4%  haemor-
hagic  cyst.
Experience  in  nephron-sparing  surgery  in  patients  with  small  ren
50%
46%
4%
TNM classification
T1aN0M0 T1bN0M0 T2aN0M0
Figure  3  TNM  cancer  staging  percentages:  14  T1a  N0  M0
patients  (50%),  13  T1b  N0  M0  patients  (46%)  and  one  T2a  N0
M0 patient  (4%).
70%
30%
Results based on lineage according to
Furhman’s classification
Furhman 2 Furhman 3
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pFigure  4  Nuclear  grade  report  in  clear  cell  tumours  according
to Fuhrman’s  classiﬁcation:  70%  Fuhrman  2  and  30%  Fuhrman  3.
Discussion
Radical  nephrectomy  was  ﬁrst  described  by  Robson  et  al.
in  1969,9 and  it  evolved  quickly,  acquiring  improved  surgical
security.  In  1987,  Czerny10 proposed  and  performed  a  partial
nephrectomy,  which  had  excellent  acceptance  among  urolo-
gists,  since  nowadays  there  are  more  sophisticated  diagnosis
imaging  where  the  position  of  the  tumour  in  relation  to  the
different  structures  can  be  evidenced.  It  is  also  favoured
with  the  use  of  more  efﬁcient  methods  to  prevent  renal
ischaemic  lesions.  All  patients  who  will  undergo  this  type  of
surgical  treatment  must  fulﬁl  a  previous  protocol  to  dismiss
a  locally  advanced  disease  or  metastasis,  as  well  as  to  deﬁne
the  association  between  the  tumour  and  the  intrarenal  blood
vessels  and  the  collection  system10.
In  patients  who  are  treated  with  partial  nephrectomy,  the
aim  is  to  preserve  the  greatest  renal  function  possible  with
r
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he  best  life  prognosis.  For  this  reason,  the  patient’s  age,
reatinine  levels  before  surgery  and  the  volume  of  resected
idney  should  be  taken  into  account.
Lopez  et  al.11 published  the  natural  development  story
or  chronic  renal  failure  in  patients  who  had  radical  nephrec-
omy  in  comparison  with  partial  nephrectomy;  assessing  the
esults  after  three  and  ﬁve  years,  with  a  sample  of  173
atients  and  113  patients,  respectively.  They  discovered  a
hronic  renal  failure-free  rate  of  89.5%  after  three  years
n  patients  who  underwent  radical  nephrectomy,  and  a  rate
f  84.8%  after  ﬁve  years.  The  rate  was  100%  after  three  and
ve  years  in  patients  who  underwent  partial  nephrectomy.11
n  our  series  of  cases,  we  observed  that  out  of  28  patients
ust  one  had  a signiﬁcant  increase  in  creatinine  levels  and
eeded  to  be  controlled  by  the  nephrology  service.  None  of
he  patients  is  doing  renal  function  replacement  therapy.
After  surgical  treatment,  in  patients  with  localised
umours,  Garcia  Galisteo  et  al.12 reported  20--30%  recur-
ence  or  metastases.  Lungs  are  the  most  commonly  affected
rgans  (50--60%  of  the  cases).  Metastasis  usually  occurs
ithin  the  ﬁrst  three  years  after  surgery.  The  disease-free
nterval  between  the  diagnosis  and  the  detection  of  the
etastatic  disease  is  associated  with  survival,  in  a  way  that
atients  whose  disease-free  interval  is  longer  have  a  higher
urvival  rate.
Up to  this  point  in  the  study,  all  patients  were  doing  a
trict  follow-up  by  having  thoracoabdominal  CT  scans  every
our  months  during  the  ﬁrst  year  and  every  six  months
fterwards,  with  no  evidence  of  local  recurrence  or  distant
etastases.
The  success  rate  of  open  partial  nephrectomies  ranges
etween  78%  and  100%.  One  of  the  main  disadvantages  is
he  risk  of  local  tumour  recurrence,  which  affects  10%  of  the
otal  of  surgeries.  It  is  possible  that  this  recurrence  is  caused
y  multifocal  and  microscopic  renal  cell  carcinoma.  In  a
eries  of  cases  studies  by  D’Armiento  et  al.13 it  was  reported
hat  the  disease-free  overall  survival  was  of  98%  in  patients
ho  made  follow-up  visits  up  to  six  years  afterwards.
A  limitation  of  our  study  was  the  follow-up  period  of
p  to  three  years,  100%  of  the  patients  were  disease-free.
owever,  this  is  a  short-term  follow-up  so  there  are  still  no
ortality  or  metastasis-free  survival  statistics.
Roos  et  al.14 established  that  nephron-sparing  surgery
educed  the  risk  of  renal  failure  in  comparison  with  radical
ephrectomy.  In  our  study,  pre-  and  postoperative  creati-
ine  levels  remained  within  normal  ranges,  with  an  average
reoperative  creatinine  level  of  0.96  mg/dl,  a  minimum  of
.5  and  a maximum  of  1.6  mg/dl;  as  well  as  an  average  post-
perative  creatinine  level  of  1.12  mg/dl,  with  a  minimum  of
.7  and  a  maximum  of  1.6  mg/dl,  which  corresponded  with
 monorenal  patient,  which  can  be  justiﬁed  and  is  similar  to
hat  established  by  worldwide  medical  bibliography.
onclusion
artial  nephrectomy  is  a  safe  oncological  procedure  in
atients  with  small  kidney  tumours,  with  positive  functional
esults  and  with  no  signiﬁcant  presence  of  alterations  in
enal  functions.  Also,  its  evolution  is  optimal  and  with  min-
mal  complications.  Patients’  quality  of  life  improves  when
hey  preserve  renal  functions.
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